&nbsp;

Jul 2023

Drug

oxaliplatin

Quick Link(s):

Oct 2023

Drug

SUNItinib

Other Name(s): Sutent®

Quick Link(s):

Sep 2023

Drug

octreotide

Other Name(s): Sandostatin® (multiple brands available) , Sandostatin® LAR™ (Novartis)

Quick Link(s):

Aug 2016

Drug

oBINutuzumab

Other Name(s): Gazyva®

Quick Link(s):

May 2022

Drug

siltuximab

Other Name(s): Sylvant®

Quick Link(s):

Mar 2025

Regimen

SUNI

Cancer Type:

Gastrointestinal,

Gastrointestinal Stromal Tumours,

Sarcoma,

GIST

Intent: Palliative

Funding:

Exceptional Access Program

SUNItinib - Unresectable or metastatic/recurrent Gastrointestinal Stromal Tumour, with specific criteria

Drugs Used:

SUNItinib

Quick Link(s):

Regimen Monograph

Oct 2020

Regimen

OCTR

Cancer Type:

Gastrointestinal,

Neuroendocrine (GI),

Lung,

Neuroendocrine (Lung)

Intent: Palliative

Funding:

ODB - General Benefit

octreotide

Drugs Used:

octreotide

Quick Link(s):

Regimen Monograph

Jun 2024

Regimen

SORA

Cancer Type:

Gastrointestinal,

Hepatobiliary / Liver / Bile Duct

Intent: Palliative

Funding:

Exceptional Access Program

SORAfenib - Advanced hepatocellular carcinoma, with specific criteria

Drugs Used:

SORAfenib

Quick Link(s):

Regimen Monograph

Mar 2023

Regimen

SUNI

Cancer Type:

Genitourinary,

Renal cell / Kidney

Intent: Palliative

Funding:

Exceptional Access Program

SUNItinib - Metastatic renal cell carcinoma, with specific criteria

Drugs Used:

SUNItinib

Quick Link(s):

Regimen Monograph

Oct 2020

Regimen

SORA

Cancer Type:

Genitourinary,

Renal cell / Kidney

Intent: Palliative

Funding:

Exceptional Access Program

SORAfenib - Metastatic renal cell carcinoma of clear cell histology as second-line treatment, with specific criteria

Drugs Used:

SORAfenib